The US Federal Drug Administration (FDA) announced on Wednesday that it had approved a third dose of the Pfizer vaccine for COVID-19 in people over the age of 65 and in people over the age of 18 who are at "high risk" of developing a serious form of the disease caused by the new coronavirus.
The booster dose can be given six months after the second.
In addition to people at "high risk" of developing severe COVID-19, the FDA has also recommended a third dose for those with "frequent exposure" to SARS-CoV-2, which also places them in the "high-risk" group. risk (manifestation) of serious complications "of the disease, he said in the press release he published.
The Advisory Committee of the Centers for Disease Control and Prevention (CDC) is expected to vote today and approve the third tranche.
The government of President Joe Biden announced in August that it intends to begin providing aid to Americans 16 years of age and older this week, following approval by the FDA and CDC.
The FDA may soon consider giving boosters to the general public, but top officials are divided on the issue, with transitional leader Janet Woodcock in favor, but scientists say current scientific evidence is not necessary.
Some countries, such as Israel and Britain, have already begun to provide aid. The United States approved booster doses for immunocompromised patients last month, and more than 2 million people have already taken them, according to the CDC.